amfAR's First Cancer Research Grants: Why a 41-Year-Old HIV Funder Is Betting $1.44 Million on T Cell Exhaustion
November 21, 2026 · 6 min read
Granted Research Team · Editorial policy
For 41 years, the American Foundation for AIDS Research has funded one disease. On November 19, 2026, it funded another.
amfAR announced three grants totaling $1.44 million for cancer research, the first in its history. Each investigator receives $480,000 over two years. By the standards of cancer funding, where the National Cancer Institute alone spends billions a year, that is a small sum. For amfAR, which says it has raised more than $950 million and awarded more than 3,900 grants since 1985, the money is less important than what it shows: one of the best-known disease-specific funders in the United States has started funding outside its disease.
The award announcement explains the reasoning, and that reasoning tells HIV and cancer researchers where the foundation's money may go next.
The Three Awards
All three projects study one problem: how to make the immune system better at recognizing and destroying cells that have gone wrong.
- Omar Abdel-Wahab, MD, Memorial Sloan Kettering Cancer Center. His lab has identified a distinct form of RNA in exhausted T cells. The project will engineer immune cells, including CAR T cells, that switch on protective genes or release immune-boosting molecules when they start to lose function.
- Ekaterina Vinogradova, PhD, The Rockefeller University. Her team will map "previously inaccessible sites on proteins" that control T cell exhaustion, then screen for small molecules that bind those sites, with the aim of drugs that restore T cell function.
- Francesca Granucci, PhD, University of Milano-Bicocca, Italy. Her group will use nanoparticles to reprogram tumor cells so they draw in more cancer-fighting immune cells, then test whether a "carefully timed intervention" improves response to immune checkpoint blockade.
Two of the three projects study T cell exhaustion. That is the state in which T cells, after long exposure to a tumor or a chronic infection, stop attacking it. Exhaustion limits how well CAR T therapies and checkpoint inhibitors work against solid tumors. It is also one of the main reasons the immune system cannot clear the HIV reservoir, the small pool of infected cells that persists even under antiretroviral therapy.
Why an HIV Funder Is Doing This
amfAR's explanation is scientific. "Both involve targeting cells of our own body, be they tumors or the HIV reservoir," said Dr. Andrea Gramatica, amfAR's vice president of research. "Breakthroughs in one can help accelerate progress in the other."
The connection has a long history. Checkpoint inhibitors, the drugs that began the modern era of cancer immunotherapy, target receptors such as PD-1. PD-1 was described in detail through chronic viral infection research before it became a cancer drug target. HIV cure researchers have since tested checkpoint inhibitors to "wake up" the reservoir, and several groups are developing CAR T cells against HIV-infected cells. In practice, cancer immunology and HIV cure research already share labs, methods and many of the same investigators.
CEO Kyle Clifford framed the move as following earlier HIV research spillovers into other fields. HIV science, he said, contributed to "Covid vaccines, cancer immunotherapies, and the idea of person-first healthcare." The grants, in amfAR's words, represent "the beginning of an expanded approach to amfAR's research investments."
There is also a funding reason, which the announcement does not state but which researchers in the field will recognize. Federal support for HIV research has been cut sharply. AVAC, the HIV prevention advocacy group, counted 191 HIV-related NIH grants terminated as of May 2025, worth more than $200 million, and NIH ended its two HIV vaccine consortia that month. The administration's budget request proposed a cut of nearly $600 million to the NIH Office of AIDS Research, according to Think Global Health. In its 2025 impact report, amfAR described stepped-up lobbying against NIH cuts.
When federal funding for one disease shrinks, a disease-specific foundation has two choices: try to fill the gap, or find scientific allies whose work moves the field forward anyway. Cancer immunology is a much larger and better-funded field than HIV cure research. Funding cancer projects whose results may apply to the HIV reservoir lets amfAR draw on that larger field without leaving its own mission.
What the Grants Do Not Tell You
The announcement leaves several questions open, and researchers should not assume answers to them.
How the projects were chosen. amfAR has not said whether the grants came from an open request for proposals, an invited competition or direct selection. Its research page lists no cancer-specific call. The only request for proposals on that page is for the Mathilde Krim Fellowships in Biomedical Research, and its letter-of-intent stage is closed.
Whether there will be a second round. amfAR calls the grants an "initial and critical step." It gives no budget, timeline or topic for any future cancer funding.
Whether the grants require HIV work. The announcement describes the HIV connection as conceptual. None of the three projects, as described, includes HIV experiments.
Who is eligible. Granucci's award to an Italian university shows the program is not limited to U.S. institutions, which matches amfAR's existing research portfolio. The foundation says it currently supports 72 researchers in seven countries.
Strategy for Researchers
If you work on T cell exhaustion, CAR T engineering or checkpoint response in cancer, amfAR is now a possible funder, but not an open one. The practical step is to know the foundation's existing programs and staff. amfAR says it funds research "often considered too preliminary for traditional funders," and its grants are known for high-risk early-stage ideas. Before writing to the foundation, a cancer immunologist should be able to say in one paragraph what their work would show about cells that persist in the body despite an immune response.
If you are an HIV cure researcher, this is a signal, not a threat. Two-thirds of the new awards study exhaustion, a core HIV cure topic. Proposals to amfAR's regular mechanisms that draw on cancer immunotherapy methods, such as engineered T cells, small-molecule exhaustion reversal and checkpoint timing, now match the stated direction of the foundation's research leadership. The 2025 impact report notes that amfAR awarded five Target grants in one funding round, a record. The foundation's core HIV cure grant programs are active.
If you run a lab affected by NIH terminations, treat amfAR as one part of a broader private funding plan, not a replacement for a federal award. The new cancer grants are $240,000 a year. That supports a postdoc and supplies, not a full R01 program. We have covered how researchers are rebuilding funding after federal cuts, and the main lesson holds here: several mid-sized private grants, tied together by a single scientific question, are more durable than waiting for one federal grant to return.
For both groups, write about the shared mechanism, not the disease. A reviewer at a foundation crossing disease lines wants to know which result will matter in both fields. "Restoring function in exhausted CD8 T cells" is a reason to fund in both cancer and HIV. "A new treatment for melanoma" fits only one.
The Bigger Pattern
amfAR is not the only disease-specific funder rethinking its scope. Many foundations started in the 1980s and 1990s around a single disease now face the same set of conditions: the science overlaps with other fields, federal support is unstable, and donors want results they can see. Some have merged. Some have started funding platform technologies that apply across diseases. amfAR's step is small and careful: three grants, two years and a stated tie to its own mission.
For researchers, the lesson is to look at disease-specific foundations for the mechanisms they study, not only for the disease named on their website. The grants for HIV cure work may come from a cancer funder, and the grants for cancer immunology may now come from an HIV funder.
Researchers looking for foundations that fund immunology, cell therapy and HIV cure work can search private and federal biomedical opportunities in Granted, and use it to adapt one research question into proposals for funders in more than one disease area.